Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations for Fosamax in Florida

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health and Science Context

For decades, general health and science communication has served as a foundational pillar for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medications. Within this legacy framework, audiences have been educated about the benefits and risks of pharmaceutical interventions, including those for chronic conditions such as osteoporosis. This established context provides a necessary baseline for recognizing that certain medications, while effective for their intended purposes, may carry unintended consequences that warrant closer scrutiny. As we move from this general health perspective toward a more specific occupational exposure concern, it becomes important to consider how individuals in certain professional settings may encounter heightened risks. In particular, those working in manufacturing, healthcare, or pharmaceutical distribution environments may have prolonged or repeated contact with substances that are not typically part of everyday consumer use. This shift in focus does not imply a direct causal link but rather acknowledges that occupational settings can alter exposure patterns, potentially influencing long-term health outcomes. The transition from broad health literacy to targeted occupational awareness allows for a more nuanced discussion of how routine workplace activities might intersect with medication-related risks, such as those associated with bisphosphonate therapies like Fosamax. This pivot sets the stage for examining specific legal and regulatory considerations, including statutes of limitations that apply in jurisdictions like Florida.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients may experience recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Clinical Presentation of ONJ

The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often with pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, and management may include conservative measures such as oral rinses, antibiotics, and limited debridement. The mechanistic pathways linking Fosamax to ONJ involve the inhibition of osteoclast-mediated bone resorption, which can impair bone remodeling and healing. Bisphosphonates accumulate in bone and can suppress turnover, particularly in the jaw, which has a high rate of remodeling. This suppression may lead to microdamage accumulation and reduced ability to repair tissue, especially after dental procedures or local trauma. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising blood supply to the jawbone. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings in informing patients and healthcare providers about the risk of ONJ may be subject to legal scrutiny, particularly in cases where patients developed ONJ after prolonged use without clear prior notification.

Statute of Limitations for Fosamax Claims in Florida

For affected patients in Florida, settlement-related considerations involve the statute of limitations for filing a claim. In Florida, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the statute is two years from the date of death. Patients who developed ONJ after using Fosamax should consult with a legal professional to determine the applicable deadlines based on their specific circumstances, including the timeline between exposure and documented harm. The timeline between exposure to Fosamax and documented harm can vary widely. ONJ may develop months to years after starting bisphosphonate therapy, and the risk increases with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who have used Fosamax for more than three to five years may be at higher risk, particularly if they undergo invasive dental procedures. Documenting the onset of symptoms and linking them to Fosamax use is critical for legal claims. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly in patients with additional risk factors and prolonged use. The prescribing information includes warnings about this risk, but the adequacy of these warnings may be questioned in litigation. Florida patients affected by ONJ should be aware of the statute of limitations and seek timely legal advice to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Florida?

In Florida, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the statute is two years from the date of death. It is important to consult with a legal professional to determine the applicable deadlines based on your specific circumstances.

What are the known risk factors for osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.